Mesoblast Annual ReportAs of August 2020, our patent portfolio...

Mesoblast Annual Report
As of August 2020, our patent portfolio includes the following patents and patent applications in the following major jurisdictions: 82 granted U.S. patents and 49 pending U.S. patent applications; 61 granted Japanese patents and 29 pending Japanese patent applications; 27 granted Chinese patents and 24 pending Chinese patent applications; 55 granted European patents and 29 pending European patent applications; and 58 granted Australian patents and 30 pending Australian patent applications.

JB- Op asked whether you were across patents for cryopreservation - hinting that may be a concern for CYP. Do you have a response? I have a lot of reading to do
as there are many granted Mesoblast US patents , not so many for Cynata.

Cynata annual report
Notable progress on patents owned directly by Cynata include the following:
z Notices of Acceptance/Allowance from IP
Australia and the Canadian Intellectual Property
Office (CIPO) regarding a patent application
entitled “Colony Forming Medium and Use
Thereof”, which relates to the optimisation of the
Cymerus process by Cynata.
Operating and Financial Review 21
z Notices of Allowance from the US Patent Office
and the CIPO for a patent application entitled
“Pluripotent Stem Cell Assay”, which relates to a
novel method for ensuring the quality and purity of
Cynata’s therapeutic MSC products
z A Notice of Acceptance from IP Australia for a
patent application titled “Method for Treating
Allergic Airways Disease (AAD/Asthma)”,
describes a method of use of Cymerus MSC
products in treating diseases of the lungs and
airways


Reg